Table 2.
Study | Case definition | Representativeness | Selection of controls | Definition of controls | Comparable for therapy | Comparable for etiology | Assessment of outcomes | Integrity of follow‐up | Quality score |
---|---|---|---|---|---|---|---|---|---|
Auezova et al.11, Lebanon | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 7 |
Bambury et al.18, Ireland | 1 | 1 | 0 | 1 | 1 | 0 | 1 | 1 | 6 |
Bao et al.19, China | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 6 |
Gandhi et al.20, India | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | 6 |
Han et al.21, China | 1 | 1 | 0 | 1 | 1 | 0 | 1 | 1 | 6 |
He et al.22, China | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 7 |
Kaya et al.23, Turkey | 1 | 1 | 0 | 1 | 1 | 0 | 1 | 1 | 6 |
Liang et al.24, China | 1 | 1 | 0 | 1 | 1 | 0 | 1 | 1 | 6 |
Lopes et al.25, Portugal | 1 | 1 | 0 | 1 | 1 | 0 | 1 | 1 | 6 |
Mason et al.26, Canada | 1 | 1 | 0 | 1 | 1 | 0 | 1 | 1 | 6 |
McNamara et al.27, Canada | 1 | 1 | 0 | 1 | 1 | 0 | 1 | 1 | 6 |
Wang et al.28, China | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 7 |
Wang et al.9, China | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 6 |
Wang et al.29, China | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 0 | 5 |
Weng et al.30, China | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 7 |
Xu et al.31, China | 1 | 1 | 0 | 1 | 1 | 0 | 1 | 1 | 6 |
Yersal et al.32, Turkey | 1 | 1 | 0 | 1 | 1 | 0 | 1 | 1 | 6 |
Zhou et al.33, China | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 7 |